Athira Historical Balance Sheet

ATHA Stock

USD 0.34 0.01 3.03%

Trend analysis of Athira Pharma balance sheet accounts such as Short Long Term Debt Total of 1.6 M, Other Current Liabilities of 11.2 M or Total Current Liabilities of 12.4 M provides information on Athira Pharma's total assets, liabilities, and equity, which is the actual value of Athira Pharma to its prevalent stockholders. By breaking down trends over time using Athira Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Athira Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Athira Pharma is a good buy for the upcoming year.

Athira Pharma Inventory

(1.48 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.

About Athira Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Athira Pharma at a specified time, usually calculated after every quarter, six months, or one year. Athira Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Athira Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Athira currently owns. An asset can also be divided into two categories, current and non-current.

Athira Pharma Balance Sheet Chart

At present, Athira Pharma's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 64.7 M, whereas Total Assets are forecasted to decline to about 55.8 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Athira Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Athira Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Athira Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Athira Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Athira Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Athira Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.At present, Athira Pharma's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 64.7 M, whereas Total Assets are forecasted to decline to about 55.8 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	1.9M	1.6M	1.2M	1.6M
Total Assets	258.2M	160.2M	58.8M	55.8M

Short Long Term Debt Total Total Assets

Athira Pharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Non Current Liabilities Other
Total Assets		0.71	0.54	0.58	1.0	0.64	0.87	-0.91	-0.29	0.69	0.9	0.93	0.34	0.51	0.7	0.99	0.82	0.71	0.99	-0.8	0.88	0.79	-0.42	1.0	0.99	0.56
Short Long Term Debt Total	0.71		0.73	0.76	0.7	0.81	0.76	-0.85	-0.6	0.58	0.86	0.5	0.54	-0.01	0.84	0.76	0.77	0.91	0.64	-0.75	0.75	0.8	0.04	0.7	0.76	0.8
Other Current Liab	0.54	0.73		1.0	0.52	0.68	0.73	-0.8	-0.8	0.4	0.81	0.23	0.94	-0.07	0.69	0.62	0.74	0.75	0.44	-0.78	0.78	0.84	0.35	0.52	0.63	0.82
Total Current Liabilities	0.58	0.76	1.0		0.56	0.7	0.75	-0.83	-0.79	0.46	0.84	0.28	0.93	-0.04	0.71	0.66	0.75	0.78	0.48	-0.81	0.81	0.86	0.32	0.56	0.66	0.83
Total Stockholder Equity	1.0	0.7	0.52	0.56		0.65	0.87	-0.91	-0.28	0.68	0.89	0.94	0.32	0.53	0.7	0.99	0.82	0.71	0.99	-0.8	0.88	0.79	-0.45	1.0	0.99	0.55
Other Liab	0.64	0.81	0.68	0.7	0.65		0.86	-0.76	-0.73	0.49	0.76	0.51	0.66	0.27	0.99	0.66	0.85	0.97	0.55	-0.84	0.8	0.87	-0.24	0.64	0.67	0.81
Net Tangible Assets	0.87	0.76	0.73	0.75	0.87	0.86		-0.94	-0.69	0.54	0.94	0.73	0.63	0.4	0.86	0.89	0.98	0.88	0.79	-0.98	0.95	0.98	-0.38	0.87	0.89	0.81
Net Debt	-0.91	-0.85	-0.8	-0.83	-0.91	-0.76	-0.94		0.6	-0.6	-1.0	-0.72	-0.63	-0.24	-0.79	-0.95	-0.93	-0.84	-0.85	0.91	-0.93	-0.94	0.16	-0.91	-0.95	-0.81
Retained Earnings	-0.29	-0.6	-0.8	-0.79	-0.28	-0.73	-0.69	0.6		-0.19	-0.64	-0.04	-0.85	0.11	-0.67	-0.35	-0.72	-0.74	-0.13	0.79	-0.65	-0.8	-0.11	-0.28	-0.35	-0.83
Accounts Payable	0.69	0.58	0.4	0.46	0.68	0.49	0.54	-0.6	-0.19		0.59	0.68	0.21	0.33	0.53	0.67	0.41	0.54	0.67	-0.53	0.65	0.54	-0.16	0.68	0.67	0.37
Cash	0.9	0.86	0.81	0.84	0.89	0.76	0.94	-1.0	-0.64	0.59		0.7	0.64	0.23	0.79	0.93	0.93	0.85	0.82	-0.93	0.94	0.95	-0.15	0.89	0.93	0.81
Non Current Assets Total	0.93	0.5	0.23	0.28	0.94	0.51	0.73	-0.72	-0.04	0.68	0.7		0.04	0.72	0.57	0.88	0.64	0.55	0.95	-0.64	0.74	0.6	-0.66	0.94	0.88	0.28
Non Currrent Assets Other	0.34	0.54	0.94	0.93	0.32	0.66	0.63	-0.63	-0.85	0.21	0.64	0.04		-0.07	0.64	0.41	0.65	0.67	0.22	-0.71	0.67	0.76	0.36	0.31	0.42	0.76
Other Assets	0.51	-0.01	-0.07	-0.04	0.53	0.27	0.4	-0.24	0.11	0.33	0.23	0.72	-0.07		0.31	0.43	0.26	0.25	0.55	-0.36	0.47	0.24	-0.71	0.53	0.43	-0.19
Long Term Debt	0.7	0.84	0.69	0.71	0.7	0.99	0.86	-0.79	-0.67	0.53	0.79	0.57	0.64	0.31		0.72	0.84	0.98	0.62	-0.83	0.82	0.87	-0.23	0.7	0.72	0.78
Cash And Short Term Investments	0.99	0.76	0.62	0.66	0.99	0.66	0.89	-0.95	-0.35	0.67	0.93	0.88	0.41	0.43	0.72		0.85	0.74	0.97	-0.82	0.89	0.83	-0.33	0.99	1.0	0.62
Net Receivables	0.82	0.77	0.74	0.75	0.82	0.85	0.98	-0.93	-0.72	0.41	0.93	0.64	0.65	0.26	0.84	0.85		0.87	0.73	-0.95	0.89	0.97	-0.33	0.82	0.85	0.87
Common Stock Shares Outstanding	0.71	0.91	0.75	0.78	0.71	0.97	0.88	-0.84	-0.74	0.54	0.85	0.55	0.67	0.25	0.98	0.74	0.87		0.62	-0.88	0.87	0.9	-0.15	0.71	0.75	0.81
Short Term Investments	0.99	0.64	0.44	0.48	0.99	0.55	0.79	-0.85	-0.13	0.67	0.82	0.95	0.22	0.55	0.62	0.97	0.73	0.62		-0.7	0.81	0.69	-0.44	0.99	0.97	0.44
Non Current Liabilities Total	-0.8	-0.75	-0.78	-0.81	-0.8	-0.84	-0.98	0.91	0.79	-0.53	-0.93	-0.64	-0.71	-0.36	-0.83	-0.82	-0.95	-0.88	-0.7		-0.97	-0.98	0.28	-0.8	-0.82	-0.8
Other Current Assets	0.88	0.75	0.78	0.81	0.88	0.8	0.95	-0.93	-0.65	0.65	0.94	0.74	0.67	0.47	0.82	0.89	0.89	0.87	0.81	-0.97		0.95	-0.25	0.88	0.9	0.7
Other Stockholder Equity	0.79	0.8	0.84	0.86	0.79	0.87	0.98	-0.94	-0.8	0.54	0.95	0.6	0.76	0.24	0.87	0.83	0.97	0.9	0.69	-0.98	0.95		-0.19	0.79	0.83	0.89
Total Liab	-0.42	0.04	0.35	0.32	-0.45	-0.24	-0.38	0.16	-0.11	-0.16	-0.15	-0.66	0.36	-0.71	-0.23	-0.33	-0.33	-0.15	-0.44	0.28	-0.25	-0.19		-0.45	-0.33	0.05
Net Invested Capital	1.0	0.7	0.52	0.56	1.0	0.64	0.87	-0.91	-0.28	0.68	0.89	0.94	0.31	0.53	0.7	0.99	0.82	0.71	0.99	-0.8	0.88	0.79	-0.45		0.99	0.54
Total Current Assets	0.99	0.76	0.63	0.66	0.99	0.67	0.89	-0.95	-0.35	0.67	0.93	0.88	0.42	0.43	0.72	1.0	0.85	0.75	0.97	-0.82	0.9	0.83	-0.33	0.99		0.63
Non Current Liabilities Other	0.56	0.8	0.82	0.83	0.55	0.81	0.81	-0.81	-0.83	0.37	0.81	0.28	0.76	-0.19	0.78	0.62	0.87	0.81	0.44	-0.8	0.7	0.89	0.05	0.54	0.63

Click cells to compare fundamentals

Athira Pharma Account Relationship Matchups

Athira Pharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	279.6M	332.0M	258.2M	160.2M	58.8M	55.8M
Short Long Term Debt Total	1M	1.9M	1.9M	1.6M	1.2M	1.6M
Other Current Liab	3.0M	8.1M	18.3M	28.3M	12.4M	11.2M
Total Current Liabilities	4.4M	9.3M	21.4M	28.8M	13.1M	12.4M
Total Stockholder Equity	274.3M	321.1M	235.1M	130.2M	44.8M	42.6M
Net Tangible Assets	(19.7M)	274.3M	321.1M	235.1M	270.4M	175.1M
Net Debt	(59.6M)	(108.6M)	(94.1M)	(89.0M)	(47.2M)	(49.6M)
Retained Earnings	(41.0M)	(95.9M)	(191.5M)	(309.2M)	(406.1M)	(385.8M)
Accounts Payable	1.2M	567K	2.5M	129K	319K	303.1K
Cash	60.6M	110.5M	96.0M	90.6M	48.4M	64.7M
Non Current Assets Total	87.2M	71.2M	50.6M	5.5M	3.9M	3.7M
Non Currrent Assets Other	132K	56K	475K	1.1M	686K	391.8K
Other Assets	84.6M	5.3M	0.0	1.0	0.9	0.86
Cash And Short Term Investments	184.7M	253.8M	200.3M	147.4M	51.3M	48.7M
Net Receivables	1.3M	2.3M	1.2M	1.6M	1.9M	1.2M
Common Stock Shares Outstanding	32.5M	36.9M	37.7M	38.0M	38.5M	35.0M
Short Term Investments	124.1M	143.2M	104.4M	56.8M	2.8M	2.7M
Liabilities And Stockholders Equity	279.6M	332.0M	258.2M	160.2M	58.8M	55.8M
Non Current Liabilities Total	876K	1.6M	1.6M	1.2M	803K	762.9K
Other Current Assets	6.4M	4.7M	6.0M	5.7M	3.6M	4.2M
Other Stockholder Equity	315.3M	417.4M	428.6M	439.7M	451.0M	322.8M
Total Liab	5.3M	10.9M	23.0M	30.1M	13.9M	19.6M
Net Invested Capital	274.3M	321.1M	235.1M	130.2M	44.8M	42.6M
Total Current Assets	192.3M	260.8M	207.5M	154.7M	54.8M	52.1M
Non Current Liabilities Other	1.0M	876K	1.6M	1.6M	1.8M	1.3M
Net Working Capital	187.9M	251.5M	186.1M	125.9M	41.7M	39.6M
Accumulated Other Comprehensive Income	33K	(388K)	(2.0M)	(349K)	1K	1.1K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:

How To Invest In Athira

Details

Is Athira Stock a good investment?

Details

What is Athira Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.52)

Return On Assets

(0.55)

Return On Equity

(1.11)

The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Athira Historical Balance Sheet

Athira Pharma Inventory

(1.48 Million)

About Athira Balance Sheet Analysis

Athira Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Athira Pharma balance sheet Correlations

Athira Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Athira Pharma balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.98	Non Current Liabilities Total
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Other Current Assets	- 0.97	Non Current Liabilities Total
Non Current Liabilities Total	- 0.95	Net Receivables
Total Current Assets	- 0.95	Net Debt